治疗急性心力衰竭患者的阿扎胺:随机对照试验的系统审查和元分析
Tanize Louize Milbradt1, Renan Yuji Ura Sudo2, Marília Oberto da Silva Gobbo3
1Division of Medicine, Federal University of Santa Maria, Santa Maria, Brazil. tanize.milbradt2@gmail.com.
Heart failure reviews
|July 10, 2024
概括
乙胺有效增强急性心力衰竭的利尿疗法,通过增加液体和分泌. 这种附加治疗改善了临床脱血,但没有增加恶化功能衰竭或死亡的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 急性心力衰竭 (AHF) 的管理通常涉及用利尿剂解决液体过载.
- 利尿剂的效率可能是有限的,需要探索辅助疗法.
- 乙醇胺降低再吸收的机制表明,它有可能增强利尿作用.
结论:
- 乙胺作为急性心力衰竭患者的有效补充疗法.
- 它增强了利尿,自然利尿和临床脱血.
- 该研究没有发现使用其会增加功能衰竭或死亡等不良事件的风险.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Antihypertensive Drugs: Thiazide-Class Diuretics
595
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
595
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


